Transmedics Group Stock Price, News & Analysis

TransMedics Group, a leader in organ transplant technology, will present at the Canaccord Genuity 42nd Annual Growth Conference on August 10, 2022, at 8:00 a.m. ET. The conference will be held at the InterContinental Boston Hotel. The management team aims to discuss advancements in portable extracorporeal warm perfusion and organ assessment technologies, which enhance organ viability and increase transplant opportunities for patients with end-stage organ failure. A live webcast will be available on their website.

TransMedics Group, Inc. (TMDX) will release its financial results for the second quarter of 2022 on August 1, 2022, after market close. A conference call will follow at 4:30 p.m. ET, allowing investors to gain insights into the company’s performance and future strategies. TransMedics specializes in portable organ perfusion and assessment technologies, aiming to enhance organ transplantation for patients with end-stage organ failure. The company is dedicated to addressing organ shortages and improving transplant outcomes.

TransMedics Group, Inc. (Nasdaq: TMDX) announced the grant of non-qualified stock options for 35,000 shares to three employees as an inducement for their employment, per Nasdaq Listing Rule 5635(c)(4). Each option has an exercise price of $28.12, equivalent to the stock's closing price on June 1, 2022. The options will vest 25% on the first anniversary and the remainder monthly over three years, subject to continued service. This initiative is part of TransMedics' strategy to enhance its workforce, focusing on organ transplant therapy for patients with end-stage organ failure.

TransMedics Group, Inc. (TMDX) reported a 125% increase in net revenue for Q1 2022, reaching $15.9 million, up from $7.1 million in Q1 2021. The company received FDA pre-market approval for OCS™ DCD heart indication and presented significant clinical trial data at ISHLT 2022. However, operating expenses rose to $21.5 million from $11.3 million, leading to a net loss of $10.6 million. The full-year revenue guidance was updated to $59 million to $65 million, reflecting a growth of 95% to 115%.

TransMedics Group announced on April 28, 2022, that the FDA granted premarket approval for its OCS™ Heart System to be used with donor hearts after circulatory death (DCD). This crucial approval expands the donor heart pool in the U.S., complementing the prior approval for brain death donors received in September 2021. The OCS™ Heart System facilitates ex vivo reanimation and functional monitoring of DCD hearts. CEO Waleed Hassanein emphasized the milestone's potential to enhance patient access to heart transplants. Final results from the OCS™ DCD Heart Trial will be presented on April 29, 2022.

TransMedics Group, Inc. (TMDX) announced on April 18, 2022, the grant of non-qualified stock options to three employees, allowing the purchase of 29,800 shares of common stock at an exercise price of $22.48. The stock options were approved by the Compensation Committee and adhere to Nasdaq Listing Rule 5635(c)(4). Vesting includes a 25% share after the first year and the remainder monthly over three years, contingent on continued employment. TransMedics focuses on organ transplant therapy innovation, enhancing organ viability and utilization for patients with end-stage organ failure.

TransMedics Group, Inc. (Nasdaq: TMDX), a leader in organ transplant technology, will announce its first-quarter 2022 financial results on May 3, 2022, after market close. A conference call to discuss these results will take place at 5:00 p.m. ET. Investors can access the call by dialing (844) 200-6205 domestically or (929) 526-1599 internationally, using Conference ID: 215877. The company aims to enhance organ preservation and assessment for transplants, addressing vital needs in heart, lung, and liver failure treatments.

TransMedics Group announces the presentation of new clinical data from its OCS™ Heart and Lung trials at the ISHLT 2022 Annual Meeting, scheduled for April 27-30, 2022, in Boston, MA. Key presentations include long-term results from the OCS DCD Heart trial and the OCS Lung EXPAND trial. These findings may significantly impact organ transplant therapy for patients with end-stage organ failure. TransMedics is set to host a symposium featuring global transplant leaders discussing their experiences with the OCS technology.

TransMedics Group, Inc. (Nasdaq: TMDX) will present virtually at the Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022, at 3:20 p.m. EST. The company is at the forefront of improving organ transplant therapy for patients with end-stage heart, lung, and liver failure. A live and archived webcast of the presentation will be available on their Investors section. TransMedics specializes in portable extracorporeal warm perfusion and assessment of donor organs, enhancing organ viability and increasing usage rates.